Study in Patients With Relapsed/Refractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context
Study in Patients With Relapsed/Refractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context
Recruiting · NCT06781450 · Registry updated 2025-01-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study in Patients With Relapsed/Refractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context | Primary Mediastinal B Cell Lymphoma | Recruiting | Not stated | 2025-01-30 | NCT06781450 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | 331 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Azienda Ospedaliera Universitaria- POLICLINICO BARI | Bari | Italy | 1 |
| Fondazione Irccs Istituto Nazionale Dei Tumori | Milan | Italy | 99 |
| IRCCS Azienda Ospedaliero - Universitaria di Bologna | Bologna | Italy | 11 |